Ang Lifesciences India Ltd (BSE: 540694) is an Amritsar, Punjab-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49 Cr, it ranks #3,802 by market cap among the 6,197 Indian listed companies on FinBizNet, and #74 of 86 in Medicinal Chemicals and Botanical Products. At ₹40.20 (as of 16 Nov 2026), the share price is 19.1% below its 52-week high of ₹49.69 and 128.0% above its 52-week low of ₹17.63. The share price is up 33.8% over one year and up 31.0% over three months.
| Current Price | ₹40.20 |
|---|---|
| Market Cap | ₹49 Cr |
| BSE Code | 540694 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -17.70% |
| Return on Assets | -1.45% |
| 52-Week Range | ₹17.63 – ₹49.69 |
| 1-Year Price Change | +33.8% |
| 3-Month Price Change | +31.0% |
| Beta (1Y) | -0.6 |
| Dividend Yield | 0.00% |
| Headquarters | Amritsar, Punjab |
| Website | anglifesciences.com |
| Revenue | ₹14 Cr |
|---|---|
| Net Profit | ₹-3 Cr |
| Net Margin | -24.5% |
| EPS (Basic) | ₹2.59 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ang Lifesciences India Ltd reported revenue of ₹14 Cr in Q1 FY27, down 43.1% from ₹25 Cr in Q1 FY26 and down 38.8% from ₹23 Cr in Q4 FY26. It posted a net loss of ₹3 Cr for the quarter, against a net loss of ₹1 Cr in Q1 FY26. Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹14 Cr (Q1 FY27) to ₹26 Cr (Q2 FY26). The company reported a net loss in 5 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹14 Cr | −₹3 Cr | −24.5% |
| Q4 FY26 | ₹23 Cr | ₹1 Cr | 4.8% |
| Q3 FY26 | ₹18 Cr | −₹4 Cr | −23.2% |
| Q2 FY26 | ₹26 Cr | −₹1 Cr | −3.1% |
| Q1 FY26 | ₹25 Cr | −₹1 Cr | −3.2% |
| Q4 FY25 | ₹18 Cr | −₹2 Cr | −11.0% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 28.80% of Ang Lifesciences India Ltd's shares as of Mar 2026, against 35.55% in Mar 2025 (−6.75 percentage points). Delivery averaged 86.9% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
ANG Lifesciences India Limited engages in manufacturing and sale of finished pharmaceutical formulations in India and internationally. Its product portfolio comprises therapeutics categories, such as antibiotics, antiviral, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, and beta lactamase inhibitor. The company offers its finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, and lotions. ANG Lifesciences India Limited was incorporated in 2006 and is based in Amritsar, India.
1. Pharmaceuticals-This segment engages in the pharmaceutical business. 2. Printing and Packagings-This segment engages in the printing and packaging business. 3. Inter Segment Revenue-0
1. Pharmaceuticals-98.6% 2. Printing and Packagings-5.2%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Ang Lifesciences India Ltd | ₹49 Cr | n/m | -17.70% | ₹14 Cr | +33.8% |
Listed by market capitalisation. Ratios are shown for context only.
Ang Lifesciences India Ltd is trading at ₹40.20, with a market capitalisation of ₹49 Cr.
Ang Lifesciences India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Ang Lifesciences India Ltd has a return on equity of -17.70%.
Ang Lifesciences India Ltd is listed on the BSE under the scrip code 540694.
Ang Lifesciences India Ltd's share price is up 33.8% over one year and up 31.0% over three months. Its 52-week range is ₹17.63 to ₹49.69.
In Q1 FY27, Ang Lifesciences India Ltd reported revenue of ₹14 Cr and net profit of ₹-3 Cr, with basic EPS of ₹2.59 (standalone, parsed from the company's exchange filing).
Ang Lifesciences India Ltd reported revenue of ₹14 Cr in Q1 FY27, down 43.1% from ₹25 Cr in Q1 FY26 and down 38.8% from ₹23 Cr in Q4 FY26.
Promoters held 28.80% of Ang Lifesciences India Ltd's shares as of Mar 2026, against 35.55% in Mar 2025 (−6.75 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.